Isoform composition of antithrombin in a covalent antithrombin-heparin complex

Biochemical and Biophysical Research Communications

Volumn 309, Issue 4, 2003, Pages 986-991

  Chan, Anthony K C ^a,b,c   Berry, Leslie R ^a,b   Paredes, Nethnapha ^a,b   Parmar, Nagina ^c  

^a HENDERSON RESEARCH CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Antithrombin (AT); Gel filtration; Heparin; Heparin affinity chromatography; Thrombin; Isoform; Isoform

Indexed keywords

ANTITHROMBIN; HEPARIN; ISOPROTEIN;

ARTICLE; BLEEDING; BLOOD CLOTTING; COMPLEX FORMATION; COVALENT BOND; DRUG EFFECT; DRUG HALF LIFE; PRIORITY JOURNAL; PROTEINASE INHIBITION; STRUCTURE ANALYSIS;

EID: 0141788157     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2003.08.109     Document Type: Article

References (36)

1. Olds R.J., Lane D.A., Mille B., Chowdhury V., Thein S.L. Antithrombin: the principal inhibitor of thrombin. Semin. Thromb. Hemost. 20:1994;353-372.
2. Risberg B. Antithrombin: facts and new hypotheses. Blood Coagul. Fibrinolysis. 9:1998;S3-S6.
3. Frebelius S., Isaksson S., Swedenborg J. Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta. Arterioscler. Thromb. Vasc. Biol. 16:1996;1292-1297.
4. Carlson T.H., Simon T.L., Atencio A.C. In vivo behaviour of human radioiodinated antithrombin III: distribution among three physiologic pools. Blood. 66:1985;13-19.
5. Peterson C.B., Blackburn M.N. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J. Biol. Chem. 260:1985;610-615.
6. Brennan S.O., George P.M., Jordan R.E. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn-135. FEBS Lett. 219:1987;431-436.
7. Picard V., Ersdal-Badju E., Bock S.C. Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity. Biochemistry. 34:1995;8433-8440.
8. Swedenborg J. The mechanism of action of alpha- and beta-isoforms of antithrombin. Blood Coagul. Fibrinolysis. 9:1998;S7-S10.
9. Witmer M.R., Hatton M.W. Antithrombin III-beta associates more readily than antithrombin III-alpha with uninjured and de-endothelialized aortic wall in vitro and in vivo. Arterioscler. Thromb. 11:1991;530-539.
10. Marcum J.A., Rosenberg R.D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry. 23:1984;1730-1737.
11. Craig P.A., Olson S.T., Shore J.D. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation, and heparin dissociation steps in the factor Xa reaction. J. Biol. Chem. 264:1989;5452-5461.
12. Bourin M., Lindhal U. Glycosaminoglycans and the regulation of blood coagulation. Biochem. J. 289:1993;313-330.
13. Estes J.W., Pelikan E.W., Kruger-Thiemer E. A retrospective study of the pharmacokinetics of heparin. Clin. Pharmacol. Ther. 10:1969;329-337.
14. Schran H.F., Bitz D.W., DiSerio F.J., Hirsh J. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. Thromb. Res. 31:1983;51-67.
15. Hirsh J., van Aken W.G., Gallus A.S., Dollery C.T., Cade J.F., Yung W.L. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 53:1976;691-695.
16. Ofosu F.A., Barrowcliffe T.W. Mechanisms of action of low molecular weight heparins and heparinoids. Baill. Clin. Haem. 3:1990;505-529.
17. Young E., Wells P., Holloway S., Weitz J., Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb. Haemost. 71:1994;300-304.
18. Hirsh J., Warkentin T.E., Raschke R., Granger C.B., Ohman E.M., Dalen J.E. Heparin and low molecular weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 114:1998;S489-S510.
19. Andersson L.O., Barrowcliffe T.W., Holmer E. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X: effect of heparin neutralization in plasma. Thromb. Res. 15:1979;531-541.
20. Bendayan P., Boccalon H., Dupouy D., Boneu B. Dermatan sulphate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Thromb. Haemost. 71:1994;576-584.
21. Chan A.K., Berry L., O'Brodovich H., Klement P., Mitchell L., Baranowski B., Monagle P., Andrew M. Covalent antithrombin-heparin complexes complexes with high anticoagulant activity: intravenous, subcutaneous and intratracheal administration. J. Biol. Chem. 272:1997;22111-22117.
22. Berry L., Chan A.K.C., Andrew M. Polypeptide-polysaccharide conjugates produced by spontaneous non-enzymatic glycation. J. Biochem. 124:1998;434-439.
23. Chan A.K.C., Berry L., Klement P., Julian J., Mitchell L., Weitz J.I., Hirsh J., Andrew M. A novel antithrombin-heparin covalent complex: antithrombotic and bleeding studies in rabbits. Blood Coagul. Fibrinolysis. 9:1998;587-595.
24. Carlson T.H., Atencio A.C. Isolation and partial characterization of two distinct types of antithrombin III from rabbit. Thromb. Res. 27:1982;23-34.
25. Romisch J., Donges R., Stauss H., Inthorn D., Muhlbayer D., Jochum M., Hoffmann J.N. Quantification of antithrombin isoform proportions in plasma samples of healthy subjects, sepsis patients, and in antithrombin concentrates. Pathophysiol. Haemost. Thromb. 32:2002;143-150.
26. Ceustermans R., Hoylaerts M., DeMol M., Collen D. Preparation, characterization, and turnover properties of heparin-antithrombin III complexes stabilized by covalent bonds. J. Biol. Chem. 257:1982;3401-3408.
27. Brieditis T.B., Bock S.C., Olson S.T., Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 36:1997;6682-6691.
28. Olson S.T., Frances-Chmura A.M., Swanson R., Bjork I., Zettlmeissl G. Effect of individual carbohydrate chains of recombinant antithrombin on heparin affinity and on the generation of glycoforms differing in heparin affinity. Arch. Biochem. Biophys. 341:1997;212-221.
29. Turk B., Brieditis I., Bock S.C., Olson S.T., Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 36:1997;6682-6691.
30. Frenoy J.P., Bourrillon R. Studies on the structure of human alpha2-macroglobulin. IV. Analysis of the microheterogeneity by isoelectric focusing. Biochim. Biophys. Acta. 371:1974;168-176.
31. Jackson C.M. Characterization of two glycoprotein variants of bovine factor X and demonstration that the factor X zymogen contains two polypeptide chains. Biochemistry. 11:1972;4873-4882.
32. Spiro R.G. Glycoproteins. Adv. Protein Chem. 27:1973;349-467.
33. Borsodi A., Narasimhan T.R. Microheterogeneity of human antithrombin III. Br. J. Haematol. 39:1978;121-127.
34. Milner A.E., Burnett D., Rutter J., Bradwell A.R. Detection of antithrombin III microheterogeneity. Thromb. Res. 37:1985;127-134.
35. Kim Y.S., Lee K.B., Linhardt R.J. Microheterogeneity of plasma glycoproteins heparin cofactor II and antithrombin III and their carbohydrate analysis. Thromb. Res. 51:2003;97-104.
36. Sakuragawa N., Kondo S., Katoh M., Takahashi K., Koide T. Antithrombin III microheterogeneity in antithrombin III deficiency and in the antithrombin III abnormality, "antithrombin III Toyama" Thromb. Res. 47:1987;147-153.